Latest Breaking News On - Hanneke schuitemaker - Page 3 : comparemela.com
Johnson & Johnson Celebrates COVID-19 Vaccine Science Superheroes
investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.
Johnson & Johnson Celebrates COVID-19 Vaccine Science Superheroes
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
The doubted scientist and her vaccine revolution
thehindu.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindu.com Daily Mail and Mail on Sunday newspapers.
•‘I am not bothered because HIV is a different virus’, says NACA DG
•Vaccine effort has not yielded success due to antigenic changes, says NARD
•Without effective vaccine, it may be difficult to eradicate disease by 2030, says Agwale
•Lack of effective vaccine for HIV still represent public health danger, says Ojo
•HIV pandemic will not just go away by discovery of vaccine, says Idoko
Unlike COVID-19, which took less than two years for scientists to develop effective vaccines, there is yet no functional Human Immuno-deficiency Virus (HIV) jab, four decades after the first cases were documented.
Indeed, the month of June marks 40 years since the first cases of HIV/Acquired Immune Deficiency Syndrome (AIDS) were documented, in 1981. Since that time, researchers and scientists have made huge strides in HIV treatment and today it is no longer a deadly disease, but rather a manageable condition.
In the three months since Johnson & Johnson’s COVID-19 vaccine received emergency use authorization from the U.S. Food and Drug Administration, more than 10 million Americans have received the vaccine, according to the Centers for Disease Control and Prevention. The single-shot viral vector vaccine developed in collaboration with Beth Israel Deaconess Medical Center (BIDMC) immunologist Dan Barouch was authorized for use based on clinical trial data showing strong clinical efficacy against symptomatic COVID-19 in the United States, Latin America and South Africa.
In a new study published in Nature, Barouch, director of BIDMC’s Center for Virology and Vaccine Research, and colleagues report on the antibody and cellular immune responses generated by the Ad26.COV2.S vaccine against the original viral strain and against SARS-CoV-2 variants of concern. The team found that this vaccine induced immune responses against all the viral variants.